Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 114

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 114
---
al Discussion: Results of Core Financial Measures (Non-IFRS Measures)

In addition to its results prepared in accordance with IFRS, on a supplemental basis, Takeda also presents the results of its Core Financial Measures. Takeda strongly encourages investors to review “ Annex to Item 5. Certain Supplemental Non-IFRS Measures as Defined and Presented by Takeda” below for more information on these metrics, including their definitions, limitations on their usefulness and reconciliations to the most directly comparable financial measures calculated and presented in accordance with IFRS. Takeda also presents period-over-period change in its Core Financial Measures on a CER % change basis; see “ Annex to Item 5. Certain Supplemental Non-IFRS Measures as Defined and Presented by Takeda” for more information.

Fiscal Year Ended March 31, 2025 compared with the Fiscal Year Ended March 31, 2024

                                                                          Billion JPY or percentage                                                                                         
                                                                          For the fiscal year ended                                           AER                                      CER  
                                                                          March 31,                                                                                                         
                                                                          2024                                         2025                   Amount of Change      % Change      % Change  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Core revenue                                                            ¥                              4,263.8          ¥      4,579.8      ¥                          7.4           2.8  
  Core operating profit                                                                                  1,054.9                 1,162.6      107.8                     10.2           4.9  
  Core net profit for the year                                            756.9                                       775.8                   18.9                       2.5         (3.4)  
  Core net profit for the year attributable to owners of the Company      756.8                                       775.6                   18.8                       2.5         (3.4)  
  Core EPS (yen)                                                          484                                           491                   7                          1.5         (4.3)  

Core Revenue

Core Revenue for the fiscal year ended March 31, 2025 was JPY 4,579.8 billion (JPY +316.1 billion and +7.4% AER, +2.8% CER). The increase was primarily attributable to favorable foreign exchange rates and growth from business momentum primarily led by Takeda’s Growth and